Serena-1: Updated analyses from a phase 1 study (parts C/D) of the next-generation oral SERD camizestrant (AZD9833) in combination with palbociclib, in women with ER-positive, HER2-negative advanced breast cancer

MLA

Mafalda Oliveira, et al. “Serena-1: Updated Analyses from a Phase 1 Study (Parts C/D) of the next-Generation Oral SERD Camizestrant (AZD9833) in Combination with Palbociclib, in Women with ER-Positive, HER2-Negative Advanced Breast Cancer.” Journal of Clinical Oncology, vol. 40, June 2022, p. 1032. EBSCOhost, https://doi.org/10.1200/jco.2022.40.16_suppl.1032.

APA

Mafalda Oliveira, Erika P. Hamilton, Jason Incorvati, Begoña Bermejo de la Heras, Emiliano Calvo, Javier García-Corbacho, Manuel Ruiz-Borrego, Christos Vaklavas, Nicholas C. Turner, Eva M. Ciruelos, Manish R. Patel, Anne C. Armstrong, Peter Kabos, Chris Twelves, Tim Brier, Itziar Irurzun-Arana, Teresa Klinowska, Justin P.O. Lindemann, Christopher J. Morrow, & Richard D. Baird. (2022). Serena-1: Updated analyses from a phase 1 study (parts C/D) of the next-generation oral SERD camizestrant (AZD9833) in combination with palbociclib, in women with ER-positive, HER2-negative advanced breast cancer. Journal of Clinical Oncology, 40, 1032. https://doi.org/10.1200/jco.2022.40.16_suppl.1032

Chicago

Mafalda Oliveira, Erika P. Hamilton, Jason Incorvati, Begoña Bermejo de la Heras, Emiliano Calvo, Javier García-Corbacho, Manuel Ruiz-Borrego, et al. 2022. “Serena-1: Updated Analyses from a Phase 1 Study (Parts C/D) of the next-Generation Oral SERD Camizestrant (AZD9833) in Combination with Palbociclib, in Women with ER-Positive, HER2-Negative Advanced Breast Cancer.” Journal of Clinical Oncology 40 (June): 1032. doi:10.1200/jco.2022.40.16_suppl.1032.